JCEM: GLP-1 receptor agonist syagogis for obesity, polycystic ovary syndrome and infertility

Obesity is responsible for the increased risk of secondary and infertilityObese women had poorer reproductive outcomes regardless of the way they conceiveed, while higher body mass index (BMI) was associated with poorer reproductive outcomesPolycystic ovary syndrome (PCOS) is one of the main causes of infertility, and many women with PCOS are also associated with overweight or obesity, a recent study published in journal Journal of Clinical Endocrinology and Metabolism, an authoritative journal for endocrine and metabolic diseases, aims to describe the mechanisms that lead to infertility and PCOS in obese/overweight women, with a focus on GLP-1 receptor agonist (GLP-1 RA) as a treatment option for obese women with PCOSweight loss is the most important factor affecting fertility and pregnancy outcomesCurrent experimental and clinical evidence suggests a potential pathophysiological link between obesity, changes in GLP-1 dynamics and PCOS pathogenesisBased on positive results in obese patients with or without diabetes, the efficacy of GLP-1 RA (mainly liraglutide) in women with obesity has been studied, either individually or in combination with metforminSeveral studies have shown that weight loss and significant reductions in testosterone are associated with insulin resistance parameters and improved menstrual proceduresit is clear that GLP-1RA's weight loss effect provides an opportunity to broaden treatment options for PCOS patients